D47.Z1Post-transplant lymphoproliferative disorder (PTLD)

D47.Z1 is the ICD-10-CM diagnosis code for Post-transplant lymphoproliferative disorder (PTLD). It belongs to category D47 (other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue), block D37-D48 (neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D47.Z (other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue), D47.Z1 is specifically for Post-transplant lymphoproliferative disorder (PTLD). Related codes cover Castleman disease (D47.Z2) and other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue (D47.Z9).

Code first: complications of transplanted organs and tissue (T86.-).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 919 (Complications of Treatment with MCC, relative weight 1.763), DRG 920 (Complications of Treatment with CC, relative weight 0.9975) and DRG 921 (Complications of Treatment without CC/MCC, relative weight 0.6722), in MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 238.77 (Post-transplant lymphoproliferative disorder (PTLD)).